CD274 and intrahepatic cholangiocarcinoma: Thus, our PEA analytics could in the future when validated in a larger cohort potentially complement PD‐L1 measurements by ICC which already have been described feasible in NSCLC FNA samples [7, 8, 9, 10, 11, 12].